Overview
Cerebrolysin is a standardized peptide preparation from porcine brain tissue consisting of low-molecular-weight neuropeptides (~75%) and free amino acids (~25%) that mimic BDNF, NGF, GDNF, and CNTF activity. Developed by EVER Neuro Pharma, it has been used clinically for over 40 years in 45+ countries.
The evidence base includes 200+ clinical studies and large RCTs such as CASTA and CARS. While results have been mixed, Cerebrolysin continues to be widely prescribed for acute ischemic stroke, TBI, vascular dementia, and Alzheimer's disease.
Cerebrolysin has never been FDA-approved, primarily due to the complexity of conducting US trials for a multi-component peptide mixture. However, it remains one of the most extensively studied neurotrophic preparations.
This guide examines its pharmacology, clinical evidence, safety data, and ongoing controversies.
Quick facts
- Mechanism
- Brain-derived peptide mixture with multi-neurotrophic activity
- Primary use
- Stroke Recovery & Neurodegenerative Disease
- Evidence
- moderate
- FDA
- Not approved
- Route
- Intravenous or intramuscular injection
- Typical results
- Neurological improvement over 3–6 months in stroke and TBI patients
Chemical information
Cerebrolysin (Peptide mixture) is a cognition compound with a molecular weight of ~10,000 g/mol (mixture). Its structural characteristics underpin its biological activity in cognitive function and neural health.
How Cerebrolysin works
Cerebrolysin activates Trk receptors (particularly TrkB), promoting neuronal survival, synaptic plasticity, and dendritic arborization through PI3K/Akt and MAPK/ERK signaling cascades.
Low molecular weight peptides (<10 kDa) cross the BBB and directly affect neurons, astrocytes, and oligodendrocytes. Key effects include synaptophysin upregulation, LTP enhancement, and reduced amyloid-β aggregation via increased α-secretase activity.
In acute stroke, Cerebrolysin reduces glutamate excitotoxicity, calcium overload, calpain-mediated damage, and inflammatory microglial activation, limiting ischemic penumbra expansion.
It promotes neurogenesis in the SVZ and hippocampus, oligodendrocyte precursor proliferation for remyelination, and peri-infarct angiogenesis for functional recovery.
- Neurotrophic factor mimicry: Mimics BDNF, NGF, GDNF, and CNTF activity
- Trk receptor activation: Activates TrkB and TrkA for neuronal survival
- BBB penetration: Low MW peptides cross the blood-brain barrier
- Synaptic enhancement: Increases synaptophysin and LTP
- Anti-apoptotic: Activates PI3K/Akt survival pathways
- Neurogenesis: Stimulates new neuron formation in SVZ and hippocampus
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability | IV or IM; 100% IV bioavailability | Typical dose: 10–30 mL IV daily for stroke; up to 50 mL for severe TBI |
| Onset of Action | Neurotrophic signaling within hours; clinical improvement over weeks | Time to measurable clinical/biological response |
| Half-life | Minutes to hours (peptides); biological effects persist longer | Determines dosing frequency |
| Duration of Effect | 10–20 day treatment courses; benefits persist months | Functional activity beyond plasma clearance |
| Metabolism | Proteolytic degradation; amino acids enter normal pools | Primary elimination pathway |
Dosing & administration
Cerebrolysin dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for Cerebrolysin is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Dizziness (~5%)
- • Headache
- • Injection site pain
- • Nausea
- • Agitation/insomnia at higher doses
- • Mild fever
Serious / potential risks
- • Allergic reactions (porcine-derived)
- • Seizures (rare, predisposed patients)
- • Contraindicated in renal failure and status epilepticus
- • Theoretical prion risk (no cases reported)
- • Diaphoresis
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| SSRIs/SNRIs | Additive serotonergic effects; monitor for serotonin syndrome | Monitor closely; dose adjustment may be required |
| Anticonvulsants | May lower seizure threshold at high doses | Monitor closely; dose adjustment may be required |
| Lithium | Both affect neurotrophic signaling; careful monitoring needed | Monitor closely; dose adjustment may be required |
| Immunosuppressants | Mild immunomodulatory properties; theoretical interaction | Generally safe; monitor if concerns arise |
Storage & handling
Injectable Solution (ampoules)
- • Room temperature (up to 25°C)
- • Protect from light
- • Do not freeze
- • 5-year shelf life sealed
Diluted Infusion
- • Dilute in 100–250 mL normal saline
- • Use within 24 hours
- • Infuse over 15–60 minutes
- • Do not mix with balanced electrolyte solutions
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Cerebrolysin is a cognition compound with research interest in neuroprotection, stroke recovery, dementia, cognition. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying cognitive function and neural health
- • Individuals interested in neuroprotection under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Heiss WD, Brainin M, Bornstein NM, et al.. Cerebrolysin in patients with acute ischemic stroke in Asia. Stroke (2012). doi: 10.1161/STROKEAHA.111.628537 PMID: 22020037
- [2] Muresanu DF, Heiss WD, Hoemberg V, et al.. Cerebrolysin and Recovery After Stroke (CARS). Stroke (2016). doi: 10.1161/STROKEAHA.115.009416 PMID: 26493674
- [3] Alvarez XA, Cacabelos R, Laredo M, et al.. Cerebrolysin in mild to moderate Alzheimer's disease. Eur J Neurol (2006). doi: 10.1111/j.1468-1331.2006.01116.x PMID: 16490040
- [4] Chen CC, Wei ST, Tsaia SC, et al.. Cerebrolysin enhances cognitive recovery of mild TBI patients. Br J Neurosurg (2013). doi: 10.3109/02688697.2013.793287 PMID: 23659179